文献速递眼底病与葡萄膜炎

非感染性葡萄膜炎患者使用二氟泼尼酯后眼压升高的风险

Risk of Elevated Intraocular Pressure With Difluprednate in Patients With Non-Infectious Uveitis.
PubMed 文献 · Am J Ophthalmol · 2022-04-02

回顾性队列研究纳入54例非感染性葡萄膜炎患者(54眼),评估局部二氟泼尼酯治疗后临床重要眼压升高的危险因素;17例(31.5%)出现眼压≥21 mmHg且较基线升高≥10 mmHg,儿童(aHR 7.85)和合并全身糖皮质激素(aHR 5.31)为显著危险因素。

要点

  • 非感染性葡萄膜炎局部二氟泼尼酯治疗后临床重要眼压升高发生率为31.5%(17/54)。
  • 儿童(aHR 7.85,95%CI 1.48-41.56,P=.02)和合并全身糖皮质激素(aHR 5.31,95%CI 1.18-24.00,P=.03)是显著危险因素。
  • 合并全身糖皮质激素者眼压升高更早(平均5.7±3.4周 vs 10.4±5.7周,P=.05)。

核心结论

  • 本研究表明,局部二氟泼尼酯治疗的非感染性葡萄膜炎患者中临床重要眼压升高较为常见。
  • 儿童和合并全身糖皮质激素的患者发生临床重要眼压升高的风险较高。

研究设计与样本

  • 回顾性队列研究,纳入当前机构接受局部二氟泼尼酯治疗的54例非感染性葡萄膜炎患者共54眼。
  • 收集人口学与临床特征,主要结局为临床重要眼压升高,定义为眼压≥21 mmHg且较基线升高≥10 mmHg。

主要发现

  • 17例(31.5%)出现临床重要眼压升高,平均发生时间7.4±4.8周(范围3-19周)。
  • 儿童发生临床重要眼压升高的校正风险比(aHR)为7.85(95%CI 1.48-41.56,P=.02)。
  • 合并全身糖皮质激素者发生临床重要眼压升高的aHR为5.31(95%CI 1.18-24.00,P=.03)。
  • 合并全身糖皮质激素者临床重要眼压升高发生更早(平均5.7±3.4周[范围3-14] vs 10.4±5.7周[范围4-19],P=.05)。
  • 7例(13.0%)发生眼压≥30 mmHg;所有患者经停用二氟泼尼酯和/或局部抗青光眼药物治疗后反应良好,无眼需青光眼手术。

关键数值与推荐

  • 临床重要眼压升高定义为眼压≥21 mmHg且较基线升高≥10 mmHg。
  • 儿童发生临床重要眼压升高的aHR 7.85(95%CI 1.48-41.56,P=.02)。
  • 合并全身糖皮质激素者发生临床重要眼压升高的aHR 5.31(95%CI 1.18-24.00,P=.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the risk factors associated with clinically important intraocular pressure (IOP) elevation with topical difluprednate treatment in patients with non-infectious uveitis. DESIGN: Retrospective cohort study. METHODS: Fifty-four eyes of 54 patients with non-infectious uveitis treated with topical difluprednate at the current institution were included. Demographics and clinical characteristics of uveitis patients were collected. The main outcome measure was development of clinically important IOP elevation defined as IOP ≥21 mmHg and an increase of ≥10 mmHg from baseline. RESULTS: A clinically important IOP elevation was observed in 17 patients (31.5%). The mean time to clinically important IOP elevation was 7.4±4.8 weeks (range 3-19). Statistically significant risk factors for incident clinically important IOP elevation were being a child (adjusted hazard ratio [aHR] 7.85 [95% CI 1.48-41.56], P = .02) and concurrent use of systemic steroids (aHR 5.31 [95% CI 1.18-24.00], P = .03). Patients with concurrent systemic corticosteroids developed clinically important IOP elevation earlier than those without systemic corticosteroid (mean 5.7±3.4 [range 3-14] vs 10.4±5.7 [range 4-19] weeks, P = .05). Incident IOP ≥30 mmHg occurred in 7 patients (13.0%). All patients responded well to the cessation of difluprednate and/or use of topical antiglaucomatous agents and no eyes required glaucoma surgery. CONCLUSIONS: This study demonstrated that clinically important IOP elevation is common in uveitis patients with topical difluprednate treatment. Children and patients with concurrent systemic corticosteroids are at substantial risk of developing clinically important IOP elevation.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Yakin M, Kumar A, Kodati S, et al. Risk of Elevated Intraocular Pressure With Difluprednate in Patients With Non-Infectious Uveitis. Am J Ophthalmol. 2022. PMID: 35381204. doi:10.1016/j.ajo.2022.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。